Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

Abstract Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials suggested greater efficacy of paxlovid, but recent studies indicated comparable potency in older adults. He...

Full description

Bibliographic Details
Main Authors:	Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Amirhossein Karimi, Nicole A. P. Lieberman, Zachary M. Sticher, Pavitra Roychoudhury, Meghan K. Andrews, Rebecca E. Krueger, Michael G. Natchus, George R. Painter, Alexander A. Kolykhalov, Alexander L. Greninger, Richard K. Plemper
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-08-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-40556-8

Similar Items

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
by: Carolin M. Lieber, et al.
Published: (2022-07-01)

Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
by: Andrea J. Haddad, et al.
Published: (2024-03-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
by: Abraham Ka-chung Wai, et al.
Published: (2023-05-01)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023-10-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
by: Kwok WC, et al.
Published: (2024-01-01)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
by: Subarna Barua, et al.
Published: (2023-08-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group, et al.
Published: (2024)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
by: V. Spiliopoulou, et al.
Published: (2023-05-01)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context
by: Eric Yuk Fai Wan, et al.
Published: (2023-10-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
by: Schilling, WHK, et al.
Published: (2023)

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
by: Davide Marangoni, et al.
Published: (2023-08-01)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
by: Victoria Kauer, et al.
Published: (2023-05-01)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2023-06-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

P1514: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY
by: Jon Salmanton-García, et al.
Published: (2023-08-01)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023-05-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023-01-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023-06-01)

Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets
by: Robert M. Cox, et al.
Published: (2024-02-01)

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
by: Kyle Rosenke, et al.
Published: (2023-02-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023-12-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
by: Haein Kim, et al.
Published: (2022-10-01)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024-01-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01)